Treatment for neuropathic pain targeting selective inhibition of MEK
选择性抑制 MEK 治疗神经性疼痛
基本信息
- 批准号:8627282
- 负责人:
- 金额:$ 28.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-01 至 2017-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAnimalsArtsBehaviorBehavioralBehavioral AssayBindingBiochemicalBiochemical PathwayBiological AssayCardiovascular systemChemical StructureChemicalsChemistryChronicClinicalClinical PharmacologyCollaborationsCommunitiesComplexComputer SimulationCore FacilityDockingDominant-Negative MutationEffectivenessEngineeringEnvironmentEtiologyEvaluationEventFinancial costFlavonoidsFlavonolsFormalinFree EnergyHealedHumanImageIn VitroInflammationInflammatoryInjection of therapeutic agentInjuryLeadLigandsMAP2K1 geneMAPK3 geneMEK inhibitionMEKsMeasuresMediatingMethodsMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesModelingModificationMolecularMolecular BankNervous system structureNeuronsNeuropathyNeurosciencesNociceptionPainPain MeasurementPain ResearchPathogenesisPharmaceutical PreparationsPhosphotransferasesPlantsPlayPropertyPsychiatryQuercetinRattusReportingResearchResearch PersonnelRodentRoleSchoolsScientistSignal TransductionSignaling MoleculeSocietiesSpinal GangliaTechniquesTestingThermal HyperalgesiasTimeTraining ProgramsTranslatingUniversitiesViralViral VectorVirusWeight-Bearing stateWisconsinWorkYangbasechemical synthesischronic constriction injurydesigneffective therapyextracellulargene therapyhealinghigh throughput screeningin vivoinhibitor/antagonistinnovationmechanical allodyniamembernerve injurynovelpainful neuropathypreferenceprogramspublic health relevancereceptorresearch studyresponsescreeningskillssmall moleculespontaneous pain
项目摘要
Abstract: Neuropathic pain resulting from chronic inflammation and injury to the nervous system is
particularly difficult to treat with the currently available drug armamentarium. Annual excess
financial cost to the society resulting from neuropathic pain-related treatment is estimated to be
$16 billion with much more in terms of lost revenue and associated immeasurable human suffering.
A novel mechanism-based treatment for neuropathic pain is clearly needed. Mitogen activated
protein kinases (MAPK) are intracellular signal transducing molecules that play a critical role in
transducing extracellular events to cellular responses. ERK1/2 and its upstream MAPK kinases
(MEK1/2) in the dorsal root ganglion (DRG) have been reported to play a role in the signaling
cascade mediating injury to neuropathic pain. We wish to test the working hypothesis that:
Selective inhibition of MEK1/2 in the dorsal root ganglion will suppress neuropathic pain. Through
3 specific aims, we propose to investigate inhibition of MEK1/2 by small molecules and a viral
vector expressing a dominant-negative MEK1 as a mechanism-based treatment for neuropathic
pain. The study involves assessment of anti-nociceptive effects of quercetin, a small molecule
flavonol compound found to inhibit MEK1/2 by binding to a region of MEK overlapping the ATP-
binding pocket, further high throughput search for other novel small molecule MEK1/2 inhibitor with
anti-nociceptive properties, modification of the small molecule through in silico docking-guided
rational chemistry, and the use of AAV2/8-DN-MEK1 to selectively inhibit this signaling in the DRG.
We employ state of art behavioral methods for in vivo analysis of effectiveness against three
rodent pain models with a strong inflammatory (paw pad formalin injection), neuropathic (spared
nerve injury), or mixed (chronic constriction injury) etiology. Traditional assessment of pain
(thermal hyperalgesia and mechanical allodynia) as well as behavioral assays for spontaneous
pain (weight bearing test and conditional place preference) will be employed. Rational chemical
modification of a lead flavonol molecule with extensive use of in silico docking of ligands to MEK
guided by the free-energy of binding as a measure of ligand affinity is proposed. The research
team consists of senior investigators with expertise in neuroscience/pain research, behavior assay
of pain, and chemical synthesis, together providing all the necessary skills to execute this project.
摘要:慢性炎症和神经系统损伤引起的神经病理性疼痛是
尤其难以用目前可用的药物医疗器械治疗。年度超额
神经性疼痛相关治疗对社会造成的经济成本估计为
160亿美元,还有更多的收入损失和相关的不可估量的人类痛苦。
显然需要一种新的基于机制的治疗神经病理性疼痛的方法。有丝分裂原激活
蛋白激酶(MAPK)是细胞内的信号转导分子,在
将细胞外事件传递给细胞反应。ERK1/2及其上游MAPK激酶
(MEK1/2)在背根节(DRG)中起信号转导作用
级联介导损伤为神经病理性疼痛。我们希望检验以下工作假设:
选择性抑制背根神经节中的MEK1/2将抑制神经病理性疼痛。穿过
3个特定目标,我们建议研究小分子和一种病毒对MEK1/2的抑制作用
表达显性-阴性MEK1的载体作为神经病机制治疗的基础
疼痛。这项研究包括评估小分子槲皮素的抗伤害性作用。
发现黄酮醇化合物通过与MEK区域重叠的ATP结合来抑制MEK1/2。
结合口袋,进一步高通量寻找其他新的小分子MEK1/2抑制剂
抗伤害性,通过硅胶对接引导的小分子修饰
合理的化学,并使用AAV2/8-dN-MEK1选择性地抑制DRG中的这一信号。
我们使用最先进的行为方法在体内分析对三个
大鼠疼痛模型具有较强的炎症性(爪垫福尔马林注射)、神经性(备用
神经损伤)或混合性(慢性缩窄性损伤)病因。传统的疼痛评估
(热痛觉过敏和机械性痛觉异常)以及自发的行为分析
将采用疼痛(负重测试和有条件的地点偏好)。合理的化学物质
黄酮醇铅分子的修饰及其在MEK电子对接中的广泛应用
在结合自由能的指导下,提出了配体亲和力的度量方法。这项研究
团队由具有神经科学/疼痛研究、行为分析专业知识的高级调查人员组成
疼痛和化学合成,共同提供了执行这一项目所需的所有技能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAY YANG其他文献
JAY YANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAY YANG', 18)}}的其他基金
Treatment for neuropathic pain targeting selective inhibition of MEK
选择性抑制 MEK 治疗神经性疼痛
- 批准号:
8976229 - 财政年份:2014
- 资助金额:
$ 28.6万 - 项目类别:
Treatment for neuropathic pain targeting selective inhibition of MEK
选择性抑制 MEK 治疗神经性疼痛
- 批准号:
8787120 - 财政年份:2014
- 资助金额:
$ 28.6万 - 项目类别:
Mitochondrial Kv1.3 potassium channels and lymphocyte apoptosis in sepsis
脓毒症中线粒体 Kv1.3 钾通道与淋巴细胞凋亡
- 批准号:
7563485 - 财政年份:2008
- 资助金额:
$ 28.6万 - 项目类别:
Mitochondrial Kv1.3 potassium channels and lymphocyte apoptosis in sepsis
脓毒症中线粒体 Kv1.3 钾通道与淋巴细胞凋亡
- 批准号:
7692893 - 财政年份:2008
- 资助金额:
$ 28.6万 - 项目类别:
Mitochondrial Kv1.3 potassium channels and lymphocyte apoptosis in sepsis
脓毒症中线粒体 Kv1.3 钾通道与淋巴细胞凋亡
- 批准号:
7933646 - 财政年份:2008
- 资助金额:
$ 28.6万 - 项目类别:
Mitochondrial Kv1.3 potassium channels and lymphocyte apoptosis in sepsis
脓毒症中线粒体 Kv1.3 钾通道与淋巴细胞凋亡
- 批准号:
8129649 - 财政年份:2008
- 资助金额:
$ 28.6万 - 项目类别:
Big MAP Kinase 1-Cx 43 Signaling in Ischemia Injury
缺血损伤中的大 MAP 激酶 1-Cx 43 信号转导
- 批准号:
7031042 - 财政年份:2005
- 资助金额:
$ 28.6万 - 项目类别:
Big MAP Kinase 1-Cx 43 Signaling in Ischemia Injury
缺血损伤中的大 MAP 激酶 1-Cx 43 信号转导
- 批准号:
7215278 - 财政年份:2005
- 资助金额:
$ 28.6万 - 项目类别:
Big MAP Kinase 1-Cx 43 Signaling in Ischemia Injury
缺血损伤中的大 MAP 激酶 1-Cx 43 信号转导
- 批准号:
7390795 - 财政年份:2005
- 资助金额:
$ 28.6万 - 项目类别:
Big MAP Kinase 1-Cx 43 Signaling in Ischemia Injury
缺血损伤中的大 MAP 激酶 1-Cx 43 信号转导
- 批准号:
6926479 - 财政年份:2005
- 资助金额:
$ 28.6万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 28.6万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 28.6万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 28.6万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 28.6万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)














{{item.name}}会员




